Pre-exposure prophylaxis for prevention of HIV

Details

• Personal Author:
  Heneine, Walid ; Thompson, Melanie ; Smith, Dawn K. ; Iskander, John K. ; Thorpe, Phoebe ; Laird, Susan
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.). Office of the Associate Director for Communication. ; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of HIV/AIDS Prevention
.
• Description:
  An estimated 50,000 individuals become infected with the human immunodeficiency virus (HIV) in the United States annually. A new prevention strategy, Pre-exposure Prophylaxis (PrEP), is intended for high-risk populations to reduce their risk of becoming infected with HIV. PrEP includes daily medication and routine follow-up. When used consistently, PrEP is shown to reduce the risk of HIV infection. If delivered effectively and used in combination with other proven prevention methods, PrEP may play a significant role in helping to address the HIV epidemic in the United States.
  
  Presented by: Walid Heneine, PhD, 
Surveillance, Antiretroviral Prophylaxis and Drug Resistance Team Lead
, Division of HIV/AIDS Prevention, 
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC [
“HIV Pre-exposure Prophylaxis (PrEP) Preclinical Research in Animal Models”]; Melanie Thompson, MD
, Founder and Principal Investigator, 
AIDS Research Consortium of Atlanta
 [“Evolving Evidence from Clinical Trials of HIV Pre-Exposure Prophylaxis”]; Dawn Smith, MD, MS, MPH, 
Biomedical Interventions Activity Lead, Prevention with Negatives Team
, Division of HIV/AIDS Prevention, 
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
 [“Program and Policy Challenges for Delivery of PrEP”].
  
  Facilitated by: John Iskander, MD, MPH, Scientific Director, Public Health Grand Rounds; 
Phoebe Thorpe, MD, MPH, Deputy Scientific Director, Public Health Grand Rounds; 
Susan Laird, MSN, RN, Communications Manager, Public Health Grand Rounds.
  
  
• Subjects:
  Anti-HIV Agents/therapeutic Use HIV Infections/epidemiology HIV Infections/prevention & Control Pre-Exposure Prophylaxis Truvada
• Source:
  Public health grand rounds ; 2014 April 22
• Document Type:
  Presentation
• Pages in Document:
  56 numbered slides
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:33089d2ac6d809f6ede935aab655e93efb8be02bb3a5ced4e95d6dcc85f807ac
• Download URL:
  https://stacks.cdc.gov/view/cdc/23202/cdc_23202_DS1.pdf
• File Type:
  [PDF - 1.47 MB ]